EUVIMEDEUVIMED entdecken
Open Access

Hepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease

Qinchao Ding iD, Feiwei Cao iD, Hui Zhuge iD, Shanglei Lai, Wenjing Cao, Haibin Wei iD, Rui Guo, Jiannan Qiu, Qing Song iD, Liuhua Pei iD, Chaolan Li iD, Caijuan Si und 4 weitere

Science Advances · 2025

DOI: 10.1126/sciadv.adt6195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Qinchao Ding und 15 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, PR. China. Hauptthemen laut MEDLINE: Liver, Nicotinamide-Nucleotide Adenylyltransferase, Fatty Liver, Alcoholic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1), a nicotinamide adenine dinucleotide (NAD + ) synthetase in Preiss-Handler and salvage pathways, governs nuclear NAD + homeostasis. This study investigated the role of NMNAT1 in alcohol-associated liver disease (ALD). Decreased NMNAT1 expression and activity were observed in the liver of patients with alcohol-associated hepatitis and either liver or primary hepatocytes from ALD mice. F-box and WD repeat domain containing 7 (FBXW7)–regulated interferon regulatory factor 1 (IRF1) ubiquitination degradation contributed to the alcohol-inhibited NMNAT1 transcriptional level. Hepatic NMNAT1 knockout aggravated alcohol-induced hepatic NAD + decline and further hepatic steatosis and liver injury. Metabolomics and transcriptomics interaction revealed that the cysteine sulfinic acid decarboxylase (CSAD)–regulated taurine pathway was involved in NMNAT1-disrupted hepatic lipid metabolism in ALD. Hepatic CSAD overexpression or taurine supply attenuated hepatic NMNAT1 knockout–aggravated ALD. Hepatic NMNAT1 loss inhibited NMN-protected ALD. Replenishing hepatic NMNAT1 reversed liver lipid accumulation in ALD mice. These findings identified NMNAT1 as a promising therapeutic target for ALD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiverNicotinamide-Nucleotide AdenylyltransferaseFatty Liver, AlcoholicAnimalsMiceHumansMice, KnockoutHepatocytesMaleLipid MetabolismDisease Models, AnimalMice, Inbred C57BLInterferon Regulatory Factor-1

Substanzen

Nicotinamide-Nucleotide AdenylyltransferaseInterferon Regulatory Factor-1

Autor:innen und Institutionen

  • School of Public Health, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, PR. China.
  • School of Life Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, PR. China.
  • Department of Kinesiology and Nutrition, University of Illinois at Chicago, Chicago, IL, USA.
  • Department of Clinical Nutrition, Affiliated Zhejiang Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, PR. China.
  • Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

ORCID-Profile: Qinchao Ding, Feiwei Cao, Hui Zhuge, Haibin Wei, Qing Song, Liuhua Pei, Chaolan Li, Zhenyuan Song, Xiaobing Dou, Songtao Li

Zitieren

APA

Ding, Q., Cao, F., Zhuge, H., Lai, S., Cao, W., Wei, H., Guo, R., Qiu, J., Song, Q., Pei, L., Li, C., Si, C., Sun, Z., Song, Z., Dou, X., & Li, S. (2025). Hepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease. Science Advances. https://doi.org/10.1126/sciadv.adt6195

Vancouver

Ding Q, Cao F, Zhuge H, Lai S, Cao W, Wei H, et al. Hepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease. Science Advances. 2025. doi:10.1126/sciadv.adt6195

BibTeX
@article{Ding2025,
  author = {Ding, Qinchao and Cao, Feiwei and Zhuge, Hui and Lai, Shanglei and Cao, Wenjing and Wei, Haibin and Guo, Rui and Qiu, Jiannan and Song, Qing and Pei, Liuhua and Li, Chaolan and Si, Caijuan and Sun, Zhaoli and Song, Zhenyuan and Dou, Xiaobing and Li, Songtao},
  title = {Hepatic NMNAT1 is required to defend against alcohol-associated fatty liver disease},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.adt6195}
}
Kostenlos starten →